Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol

Fig. 1

Study design of CONFIDENCE. CONFIDENCE comprises two cohorts, the ocrelizumab cohort and the other DMT cohort. Recruitment into the ocrelizumab cohort started in April 2018, while recruitment into the other DMT cohort will start in Q2 2019. The observation period is planned to continue until the third quarter of 2028. Observation per patient will be 7.5 years (90 months) to 10 years (120 months; in the ocrelizumab cohort) depending on the time of inclusion. Visits follow routine practice and are expected to be documented every 6 months. FPI, first patient in; LPO, last patient out; Q, quarter

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us